electroCore (NASDAQ:ECOR) Given New $26.00 Price Target at LADENBURG THALM/SH SH

electroCore (NASDAQ:ECOR) had its price target trimmed by LADENBURG THALM/SH SH from $28.00 to $26.00 in a report published on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of electroCore in a report on Thursday.

electroCore Stock Down 26.5 %

electroCore stock opened at $9.55 on Thursday. The company’s 50-day moving average price is $16.16 and its 200-day moving average price is $12.26. The company has a market cap of $63.56 million, a PE ratio of -5.22 and a beta of 0.24. electroCore has a twelve month low of $5.32 and a twelve month high of $19.49.

Hedge Funds Weigh In On electroCore

Large investors have recently made changes to their positions in the company. Renaissance Technologies LLC lifted its stake in electroCore by 80.6% in the fourth quarter. Renaissance Technologies LLC now owns 131,786 shares of the company’s stock worth $2,136,000 after purchasing an additional 58,800 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of electroCore by 10.3% in the third quarter. Geode Capital Management LLC now owns 63,485 shares of the company’s stock worth $458,000 after buying an additional 5,951 shares during the period. HighTower Advisors LLC bought a new stake in shares of electroCore during the 3rd quarter worth approximately $255,000. Marshall Wace LLP purchased a new position in electroCore during the 4th quarter valued at $438,000. Finally, Jane Street Group LLC bought a new position in electroCore in the 4th quarter valued at $278,000. 26.74% of the stock is owned by hedge funds and other institutional investors.

electroCore Company Profile

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.